About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker AGIO · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Oct 30, 2026A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Depend…
NCT04770753 · Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusio…
Placebo Matching Mitapivat, Mitapivat
AGIO
Agios Pharmaceuticals, Inc.
Phase 3Active, not recruiting194Nov 13, 2023Registry ↗
Oct 29, 2026A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Partici…
NCT07506863 · Transfusion-dependent Alpha-Thalassemia, Transfusion-depend…
Mitapivat Matched Placebo, Mitapivat
AGIO
Agios Pharmaceuticals, Inc.
Phase 3Recruiting54Jun 2029Registry ↗
Oct 28, 2026A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell D…
NCT07656415 · Sickle Cell Disease
Mitapivat Matched Placebo, Mitapivat
AGIO
Agios Pharmaceuticals, Inc.
Phase 3Recruiting159Aug 2029Registry ↗
Oct 28, 2026A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Partici…
NCT07517133 · Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusio…
Mitapivat, Placebo Matching Mitapivat
AGIO
Agios Pharmaceuticals, Inc.
Phase 3Recruiting45Mar 2029Registry ↗
Oct 28, 2026A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subje…
NCT07241234 · Phenylketonuria
AG-181
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Recruiting20Jan 17, 2028Registry ↗
Oct 28, 2026A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell D…
NCT06924970 · Sickle Cell Disease
Tebapivat, Tebapivat Matched Placebo
AGIO
Agios Pharmaceuticals, Inc.
Phase 2Active, not recruiting59May 12, 2026Registry ↗
Oct 28, 2026A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Spo…
NCT05777993 · Pyruvate Kinase Deficiency, Anemia, Hemolytic
Mitapivat
AGIO
Agios Pharmaceuticals, Inc.
Phase 4Enrolling by invitation55Aug 2029Registry ↗
Oct 28, 2026A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Ki…
NCT05175105 · Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic A…
Mitapivat, Mitapivat-matching placebo
AGIO
Agios Pharmaceuticals, Inc.
Phase 3Active, not recruiting30Dec 13, 2024Registry ↗
Oct 28, 2026A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Ki…
NCT05144256 · Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic A…
Mitapivat, Mitapivat-matching placebo
AGIO
Agios Pharmaceuticals, Inc.
Phase 3Active, not recruiting49May 3, 2024Registry ↗
Oct 28, 2026A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent…
NCT04770779 · Transfusion-dependent Alpha-Thalassemia, Transfusion-depend…
Placebo Matching Mitapivat, Mitapivat
AGIO
Agios Pharmaceuticals, Inc.
Phase 3Active, not recruiting258Apr 11, 2024Registry ↗
Oct 28, 2026Pyruvate Kinase Deficiency Global Longitudinal Registry
NCT03481738 · Pyruvate Kinase Deficiency
AGIO
Agios Pharmaceuticals, Inc.
—Active, not recruiting500May 31, 2027Registry ↗
Oct 26, 2026A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell D…
NCT05031780 · Sickle Cell Disease
Mitapivat, Mitapivat-matching placebo
AGIO
Agios Pharmaceuticals, Inc.
Phase 2/3Active, not recruiting286Oct 30, 2025Registry ↗
Oct 13, 2026A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera
NCT07859423 · Polycythemia Vera
AG-236, Placebo
AGIO
Agios Pharmaceuticals, Inc.
Phase 2/3Not yet recruiting245Aug 2030Registry ↗
Sep 28, 2026A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndrom…
NCT05490446 · Myelodysplastic Syndromes
Tebapivat
AGIO
Agios Pharmaceuticals, Inc.
Phase 2Active, not recruiting87Mar 17, 2026Registry ↗
Jul 30, 2026A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and…
NCT07075640 · Healthy Participants
AG-236, Placebo
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Active, not recruiting24Feb 11, 2026Registry ↗
May 1, 2026A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency
NCT02476916 · Pyruvate Kinase Deficiency
AG-348
AGIO
Agios Pharmaceuticals, Inc.
Phase 2Completed52May 8, 2017Registry ↗
Apr 3, 2026A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy
NCT06286046 · Sickle Cell Disease, Nephropathy
Mitapivat
AGIO
Agios Pharmaceuticals, Inc.
Phase 2Withdrawn0May 2027Registry ↗
Mar 30, 2026A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adul…
NCT03692052 · Thalassemia
AG-348
AGIO
Agios Pharmaceuticals, Inc.
Phase 2Active, not recruiting20Aug 20, 2020Registry ↗
Dec 23, 2025Single and Multiple Ascending Dose Study and Food Effect Study for AG181
NCT06286033 · Healthy Volunteers
AG-181, Placebo
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed88Oct 9, 2025Registry ↗
Nov 18, 2025Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled…
NCT03853798 · Pyruvate Kinase Deficiency
Mitapivat
AGIO
Agios Pharmaceuticals, Inc.
Phase 3Completed90Jul 3, 2024Registry ↗
Mar 18, 2025A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Exte…
NCT06745271 · Healthy Participants
[14C]-tebapivat, [13C2,15N3]-tebapivat
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed8Feb 21, 2025Registry ↗
Jan 28, 2025Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants
NCT06648824 · Healthy Participants
Mitapivat, Midazolam
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed20Dec 3, 2024Registry ↗
Apr 16, 2024A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Hea…
NCT04536792 · Healthy Volunteers, Anemia, Sickle Cell
AG-946, AG-946 Matched Placebo
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed122Dec 19, 2023Registry ↗
Oct 16, 2023Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008
NCT04995315 · Pyruvate Kinase Deficiency
AGIO
Agios Pharmaceuticals, Inc.
—Completed13Sep 22, 2023Registry ↗
Sep 21, 2023A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to M…
NCT05610657 · Moderate Hepatic Impairment
Mitapivat
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed20Jul 21, 2023Registry ↗
Sep 7, 2023Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)
NCT04964323 · Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anem…
AGIO
Agios Pharmaceuticals, Inc.
—Terminated15Jun 30, 2023Registry ↗
May 24, 2022A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants Wi…
NCT03548220 · Pyruvate Kinase Deficiency, Anemia, Hemolytic
Placebo, AG-348
AGIO
Agios Pharmaceuticals, Inc.
Phase 3Completed80Oct 9, 2020Registry ↗
Jan 4, 2022A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants Wit…
NCT03559699 · Pyruvate Kinase Deficiency, Anemia, Hemolytic
AG-348
AGIO
Agios Pharmaceuticals, Inc.
Phase 3Completed27Nov 12, 2020Registry ↗
Jul 21, 2021A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect…
NCT04128787 · Healthy Volunteers
AG881 Formulation 1, AG881 Formulation 2
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed36Dec 18, 2019Registry ↗
Apr 13, 2021A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mita…
NCT04696393 · Healthy Volunteers
Mitapivat tablet
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed26Mar 19, 2021Registry ↗
Feb 18, 2021A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy…
NCT04472832 · Healthy Volunteers
Placebo for Treatment A, Mitapivat 100 mg
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed32Nov 23, 2020Registry ↗
Dec 10, 2020A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation…
NCT04565678 · Healthy Volunteers
Mitapivat tablets, Mitapivat coated granules
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed32Dec 3, 2020Registry ↗
Aug 25, 2020A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
NCT03834584 · Lymphoma
AG-636
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Terminated11Jun 17, 2020Registry ↗
Apr 2, 2020A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants
NCT04145128 · Healthy Volunteers
AG881
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed32Dec 11, 2019Registry ↗
Mar 16, 2020Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma
NCT03361358 · Advanced Solid Tumors, Lymphoma
AGIO
Agios Pharmaceuticals, Inc.
—Completed44Sep 30, 2019Registry ↗
Oct 23, 2019Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Phar…
NCT03991312 · Healthy Volunteers
itraconazole, rifampin
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed28Aug 14, 2019Registry ↗
Oct 23, 2019A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration…
NCT03960502 · Healthy Male Participants
AG-881, [13C315N3]AG-881
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed5Sep 7, 2019Registry ↗
Oct 14, 2019A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in…
NCT04015687 · Healthy Participants
AG-881, Lamotrigine
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed22Oct 9, 2019Registry ↗
Mar 8, 2019Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1…
NCT02492737 · Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome
AG881
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed46Mar 21, 2018Registry ↗
Oct 12, 2018A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailabilit…
NCT03703505 · Healthy Volunteers
AG-348, [13C6]AG-348
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed8Jun 1, 2018Registry ↗
Jul 24, 2018Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation
NCT03245424 · Acute Myeloid Leukemia, Relapsed Adult AML
ivosidenib (AG-120)
AGIO
Agios Pharmaceuticals, Inc.
—Approved for marketing——Registry ↗
Apr 27, 2018A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepat…
NCT03282513 · Hepatic Impairment
AG-120 (Ivosidenib)
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed33Mar 31, 2018Registry ↗
Jan 12, 2018Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulat…
NCT03397329 · Healthy Volunteers
AG-348 Sequence A, AG-348 Sequence B
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed26Nov 13, 2017Registry ↗
Jan 11, 2018Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects
NCT03071770 · Healthy
ivosidenib (AG-120)
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed60May 9, 2017Registry ↗
Oct 19, 2017Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Jap…
NCT03250598 · Healthy, Japanese
AG-348, AG-348
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed60Oct 2, 2017Registry ↗
Jun 29, 2017A Safety and Tolerability Study of AG-519 in Healthy Subjects
NCT02630927 · Anemia
AG-519, Placebo
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Terminated108Dec 2016Registry ↗
Jun 27, 2017Drug-Drug Interaction Study of AG120 in Healthy Subjects
NCT02831972 · Healthy
AG120, Itraconazole
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed22Sep 2016Registry ↗
Nov 29, 2016Food Effect Study of AG120 in Healthy Subjects
NCT02579707 · Healthy
AG120
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed36Feb 2016Registry ↗
Dec 14, 2015Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120
NCT02489513 · Healthy Volunteers
[14C]-AG-120
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed8Sep 2015Registry ↗
Dec 14, 2015Food Effect Study of AG-221 in Healthy Male Subjects
NCT02218346 · Healthy Volunteers
AG221
AGIO
Agios Pharmaceuticals, Inc.
Phase 1Completed30Dec 2014Registry ↗

50 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:51 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances